<DOC>
	<DOCNO>NCT02706678</DOCNO>
	<brief_summary>The objective study evaluate effect tacrolimus sustained-release capsule replace cyclosporin kidney function renal transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Study Switch From Cyclosporin Tacrolimus Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1865 year age , male female 15 year kidney transplantation The patient accept cyclosporinbased immunosuppressive therapy ≥6 month , therapeutic regimen keep stable least 4 week inclusion The dose cyclosporin keep stable least 4 week inclusion At least one cyclosporinrelated adverse reaction present answer 5th question questionnaire `` Yes '' time inclusion : gingival hyperplasia treatment request patient polytrichia interventional therapy request patient posttransplantation hypertension posttransplantation hyperlipemia ( total cholesterol &gt; 5.7 mmol/L ( 220 mg/dl ) ) Serum creatinine &lt; 200 μmol/l ( 2.3 mg/dl ) A promise make take contraceptive measure study ( woman childbearing age ) . Patients accepted transplantation organ apart kidney transplantation Patients 24hour urine protein &gt; 2 g Patients SGPT/ALT , SGOT/AST total bilirubin continually increase twice normal value ( ) Patients refractory infectious focus Patients serious diarrhea vomiting , active upper gastrointestinal ulcer malabsorption Patients serious heart lung diseases history sugar tolerance abnormality malignant tumor Patients allergic tacrolimus basic medication Pregnant lactate woman Patients participate clinical trial within previous month Other patient consider doctor unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FK506</keyword>
	<keyword>Renal transplant recipient</keyword>
	<keyword>cyclosporin</keyword>
</DOC>